Mutamycin

Glaucoma, Mesothelioma, Breast Cancer + 7 more
Treatment
6 FDA approvals
20 Active Studies for Mutamycin

What is Mutamycin

MitomycinThe Generic name of this drug
Treatment SummaryMitomycin is an antibiotic used to treat cancer. It was first discovered in the 1950s by Japanese microbiologists and works by inhibiting the replication of DNA. It is an alkylating agent, which means it creates a cross-link between the two strands of the DNA double helix. Few other antibiotics have this same type of effect, making it a rare and unique treatment option. Mitomycin has been approved for use in a variety of cancers, as well as to reduce eye pressure during certain surgeries.
Mutamycinis the brand name
image of different drug pills on a surface
Mutamycin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mutamycin
Mitomycin
1981
46

Approved as Treatment by the FDA

Mitomycin, also called Mutamycin, is approved by the FDA for 6 uses such as ab externo surgery Glaucoma and Adenocarcinomas of the Pancreas .
ab externo surgery Glaucoma
Adenocarcinomas of the Pancreas
Used to treat Adenocarcinomas of the Pancreas in combination with null
Adenocarcinoma of the Stomach
Used to treat Adenocarcinoma of the Stomach in combination with null
Gastric Adenocarcinoma
Used to treat Adenocarcinoma of the Stomach in combination with null
Pancreatic Adenocarcinoma
Used to treat Adenocarcinomas of the Pancreas in combination with null
Glaucoma

Effectiveness

How Mutamycin Affects PatientsMitomycin is an older chemotherapy drug that has been used for many years. It is an antibiotic and can help fight tumors. Mitomycin works by blocking DNA, RNA, and protein synthesis. It also can prevent cells such as B cells, T cells, and macrophages from growing, and can stop certain substances like interferon gamma, TNFa, and IL-2 from being released.
How Mutamycin works in the bodyMitomycin is activated in the body to a form that binds to DNA and prevents it from functioning properly. This binding causes areas of the DNA to link together, preventing it from replicating. Mitomycin works in all phases of the cell cycle and doesn't discriminate against any.

When to interrupt dosage

The amount of Mutamycin is contingent upon the diagnosed condition, including Gastric Adenocarcinoma, Cervical Cancer and Glaucoma. The dosage can also be found in the table below, contingent upon the method of delivery.
Condition
Dosage
Administration
Head and Neck Neoplasms
, 2.0 mg/mL, 0.5 mg/mL, 4.0 mg/mL, 20.0 mg, 5.0 mg, 0.2 mg/mL, 40.0 mg
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous; Intravesical, Powder, for solution, Intravenous; Intravesical, Kit, Solution - Ophthalmic, Ophthalmic, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Ureteral, Kit - Ophthalmic
Glaucoma
, 2.0 mg/mL, 0.5 mg/mL, 4.0 mg/mL, 20.0 mg, 5.0 mg, 0.2 mg/mL, 40.0 mg
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous; Intravesical, Powder, for solution, Intravenous; Intravesical, Kit, Solution - Ophthalmic, Ophthalmic, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Ureteral, Kit - Ophthalmic
Mesothelioma
, 2.0 mg/mL, 0.5 mg/mL, 4.0 mg/mL, 20.0 mg, 5.0 mg, 0.2 mg/mL, 40.0 mg
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous; Intravesical, Powder, for solution, Intravenous; Intravesical, Kit, Solution - Ophthalmic, Ophthalmic, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Ureteral, Kit - Ophthalmic
Breast Cancer
, 2.0 mg/mL, 0.5 mg/mL, 4.0 mg/mL, 20.0 mg, 5.0 mg, 0.2 mg/mL, 40.0 mg
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous; Intravesical, Powder, for solution, Intravenous; Intravesical, Kit, Solution - Ophthalmic, Ophthalmic, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Ureteral, Kit - Ophthalmic
Gastric Adenocarcinoma
, 2.0 mg/mL, 0.5 mg/mL, 4.0 mg/mL, 20.0 mg, 5.0 mg, 0.2 mg/mL, 40.0 mg
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous; Intravesical, Powder, for solution, Intravenous; Intravesical, Kit, Solution - Ophthalmic, Ophthalmic, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Ureteral, Kit - Ophthalmic
Non-Small Cell Lung Cancer
, 2.0 mg/mL, 0.5 mg/mL, 4.0 mg/mL, 20.0 mg, 5.0 mg, 0.2 mg/mL, 40.0 mg
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous; Intravesical, Powder, for solution, Intravenous; Intravesical, Kit, Solution - Ophthalmic, Ophthalmic, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Ureteral, Kit - Ophthalmic
Anus Neoplasms
, 2.0 mg/mL, 0.5 mg/mL, 4.0 mg/mL, 20.0 mg, 5.0 mg, 0.2 mg/mL, 40.0 mg
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous; Intravesical, Powder, for solution, Intravenous; Intravesical, Kit, Solution - Ophthalmic, Ophthalmic, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Ureteral, Kit - Ophthalmic
Bladder Cancer
, 2.0 mg/mL, 0.5 mg/mL, 4.0 mg/mL, 20.0 mg, 5.0 mg, 0.2 mg/mL, 40.0 mg
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous; Intravesical, Powder, for solution, Intravenous; Intravesical, Kit, Solution - Ophthalmic, Ophthalmic, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Ureteral, Kit - Ophthalmic
Pancreatic Adenocarcinoma
, 2.0 mg/mL, 0.5 mg/mL, 4.0 mg/mL, 20.0 mg, 5.0 mg, 0.2 mg/mL, 40.0 mg
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous; Intravesical, Powder, for solution, Intravenous; Intravesical, Kit, Solution - Ophthalmic, Ophthalmic, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Ureteral, Kit - Ophthalmic
low-grade Upper Tract Urothelial Cancer (LG-UTUC)
, 2.0 mg/mL, 0.5 mg/mL, 4.0 mg/mL, 20.0 mg, 5.0 mg, 0.2 mg/mL, 40.0 mg
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous; Intravesical, Powder, for solution, Intravenous; Intravesical, Kit, Solution - Ophthalmic, Ophthalmic, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Ureteral, Kit - Ophthalmic

Warnings

Mutamycin Contraindications
Condition
Risk Level
Notes
increase in bleeding tendency
Do Not Combine
Low Platelet Count
Do Not Combine
Blood Coagulation Disorders
Do Not Combine
There are 20 known major drug interactions with Mutamycin.
Common Mutamycin Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Mitomycin is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Mitomycin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Mitomycin is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Mitomycin is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Mitomycin is combined with Acteoside.
Mutamycin Toxicity & Overdose RiskThe toxic dose of the drug in mice has been found to be 23mg/kg and 30mg/kg in rats. Those who overdose on the drug may experience nausea and vomiting.

Mutamycin Novel Uses: Which Conditions Have a Clinical Trial Featuring Mutamycin?

There are presently 1386 investigations in progress, assessing the potential of Mutamycin in managing Cervical Cancer, Bladder Cancer and Pancreatic Adenocarcinoma.
Condition
Clinical Trials
Trial Phases
Bladder Cancer
101 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1
Gastric Adenocarcinoma
33 Actively Recruiting
Phase 4, Phase 2, Phase 1, Phase 3
Glaucoma
0 Actively Recruiting
Breast Cancer
21 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Mesothelioma
0 Actively Recruiting
low-grade Upper Tract Urothelial Cancer (LG-UTUC)
0 Actively Recruiting
Anus Neoplasms
18 Actively Recruiting
Phase 2, Not Applicable, Phase 3, Phase 1
Pancreatic Adenocarcinoma
62 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Non-Small Cell Lung Cancer
358 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1
Head and Neck Neoplasms
6 Actively Recruiting
Phase 3, Not Applicable, Phase 1

Mutamycin Reviews: What are patients saying about Mutamycin?

3Patient Review
9/18/2014
Mutamycin for Cancer of the Bladder
The doctor administered this treatment via a catheter, which was uncomfortable but not painful. A few days after each treatment, I experienced a low-grade fever--this happened after every single treatment. I received six treatments in total, on a weekly basis. It's too soon to tell if the treatment was effective or not.
3Patient Review
2/28/2020
Mutamycin for Cancer of the Bladder
The surgery to remove the tumor was successful, and now I've started chemo. So far it's been tough because of fatigue, but it's only my third treatment.
3Patient Review
9/18/2014
Mutamycin for Cancer of the Bladder
The doctor administering this treatment was via a catheter, which was uncomfortable but not painful. A few days after each treatment, I experienced a low-grade fever similar to the flu. This happened after every weekly treatment. It's too soon to tell if the treatments were effective.
3Patient Review
2/28/2020
Mutamycin for Cancer of the Bladder
The surgery to remove the tumor went well, and chemo has been manageable so far. The fatigue has been the worst part, but I'm almost done with treatment.
1.3Patient Review
3/11/2010
Mutamycin for Cancer of the Bladder
Unfortunately, this medication caused a number of issues for me, including a skin rash, fatigue, and irritation/itching around my bladder and urethra.
1.3Patient Review
3/11/2010
Mutamycin for Cancer of the Bladder
I unfortunately had a lot of negative side effects from this treatment, including a skin rash, fatigue, and irritation/itching around my bladder and urethra.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about mutamycin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How do you give a Mitomycin injection?

"In cytostatic monochemotherapy mitomycin is usually given as an intravenous injection all at once. The recommended dosage is 10 - 20 mg/m2 of body surface every 6 - 8 weeks, 8 - 12 mg/m2 of body surface every 3 - 4 weeks, or 5-10 mg/m2 of body surface every 1-6 weeks depending on which therapeutic scheme is used."

Answered by AI

When is Mitomycin used for bladder cancer?

"The chemotherapy drug Mitomycin is used to kill any cancer cells that may have remained in your bladder after surgery. The drug remains in your bladder for one to two hours and is then drained out through the urinary catheter, or leaves your bladder when you pass urine."

Answered by AI

What is Mitomycin used for?

"Mitomycin is an antibiotic that is only used in cancer chemotherapy. It slows or stops the growth of cancer cells."

Answered by AI

Is Mitomycin a chemotherapy?

"Mitomycin C is a chemotherapy drug that treats various types of cancer."

Answered by AI

Clinical Trials for Mutamycin

Image of Johns Hopkins Hospital in Baltimore, United States.

Intravenous Fluids for Bladder Cancer

18+
All Sexes
Baltimore, MD
Radical cystectomy is the standard of care for muscle invasive bladder cancer, however despite advances, it is still associated with high morbidity. Many complications may be driven by dehydration and it is unclear if a home intravenous fluid (IVF) infusion program post-operatively, which is an accepted standard practice, is beneficial. This study is a single institution randomized controlled trial where patients who choose to undergo radical cystectomy for bladder cancer will be randomized to an Enhanced Recovery After Surgery (ERAS) protocol with a home IVF program, consisting of 1 liter (L) of crystalloid fluid three times per week for four weeks, or ERAS protocol alone. The primary outcome will be 90-day hospital re-admissions, with secondary outcomes including 30 and 90 day complications.
Recruiting
Has No Placebo
Johns Hopkins HospitalMax Kates, MD
Have you considered Mutamycin clinical trials? We made a collection of clinical trials featuring Mutamycin, we think they might fit your search criteria.Go to Trials
Image of University of California, San Diego Moores Cancer Center in La Jolla, United States.

Retifanlimab + Ruxolitinib for Kidney and Lung Cancer

Any Age
All Sexes
La Jolla, CA
The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma. The main question it aims to answer is: What is the maximum dose of ruxolitinib that can be used safely in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma, and will it work? Participants will: Take drug ruxolitinib twice a day and keep a diary of when they take ruxolitinib at home; visit the clinic for infusions of retifanlimab every 4 weeks; visit the clinic for checkups and tests.
Phase 1 & 2
Waitlist Available
University of California, San Diego Moores Cancer CenterRana McKayIncyte Corporation
Have you considered Mutamycin clinical trials? We made a collection of clinical trials featuring Mutamycin, we think they might fit your search criteria.Go to Trials
Image of Carolina Biooncology in Huntersville, United States.

RNDO-564 + Pembrolizumab for Bladder Cancer

18+
All Sexes
Huntersville, NC
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab. The study is focused on participants with certain solid tumors that are in an advanced stage and have certain tumor makers. This will be done by measuring the side effects that participants experience and how severe they are. Additionally, the study will evaluate how RNDO-564 moves into, through, and out of the body and how the treatment affects the body. The second goal of this study is to evaluate how well RNDO-564 works by itself or in combination with pembrolizumab at treating participants' cancer. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured. Participants will take RNDO-564 weekly on Days 1, 8 and 15 of a 21 day cycle. Participants in the combination arms will take RNDO-564 as described with pembrolizumab every 3 weeks.
Phase 1
Recruiting
Carolina Biooncology (+1 Sites)Thomas Manley, MDRondo Therapeutics
Image of Ohio State University Comprehensive Cancer Center in Columbus, United States.

Psilocybin-Assisted Therapy for Depression in Lung Cancer

18+
All Sexes
Columbus, OH
This phase II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of major depressive disorder in patients with non-small cell lung cancer. A cancer diagnosis is life-changing, resulting in significant levels of psychological symptoms, including a combination of depression, anxiety, stress, including feelings of existential distress (i.e., loss of meaning, demoralization, despair). Among all cancer patients, those diagnosed with lung cancer have the highest prevalence of mood disorders, such as depression (up to 40%) leading to profound deterioration in quality of life, prolonged hospital stays, poorer treatment adherence, decreased survival rates, and high rates of suicide (5- and 3-times higher than the general population and other cancer patients, respectively). Psilocybin is substance being studied in the treatment of anxiety or depression in patients with advanced cancer. It is taken from the mushroom Psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). Psilocybin in combination with therapy may be safe and effective in treating major depressive disorder in patients with non-small cell lung cancer.
Phase 2
Waitlist Available
Ohio State University Comprehensive Cancer CenterAlan K Davis, PhD
Image of University of Arizona Cancer Center in Tucson, United States.

Exercise for Lung Cancer

18+
All Sexes
Tucson, AZ
There is increased interest and knowledge about the lung cancer tumor microenvironment (TME). Investigators hypothesize that patients with better baseline physiologic health will have better post-operative outcomes and that strenuous exercise will alter the TME and genetic make-up of the tumor, improving the tumor immune response. Investigators aim to identify the peri-operative and clinical outcomes that differ based on pre-operative VO2max, HRV and resting heart rate following resection of early-stage lung cancer. The physiologic states that are individual and measurable with wearable devices include but are not limited to VO2max, heart rate variability (HRV), and average resting heart rate. Investgators hypothesize that a patient's pre-operative physiologic function with higher VO2max, HRV and lower resting heart rate will be associated with improved peri-operative and post-operative outcomes. Second, investigators will compare alterations in TME based on targeted pre-operative exercise (60-80% of their VO2 max for 75min/week x2 weeks) compared to normal activity adults following resection of early-stage lung cancer. Investigators hypothesize that strenuous exercise in the pre-operative period will impact the TME by increasing levels of cytokines.
Waitlist Available
Has No Placebo
University of Arizona Cancer CenterStephanie Worrell, MD
Have you considered Mutamycin clinical trials? We made a collection of clinical trials featuring Mutamycin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security